References
1. LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005 Apr 4;352(14):142535.
2. Pitt B. Lowdensity lipoprotein cholesterol in patients with stable coronary heart disease—is it time to shift our goals? N Engl J Med. 2005 Apr 7;352(14):14834.
3. Amarenco P, Bogousslavasky J, Callahan A, et al. Highdose atorvastatin after stroke or transient ischemic attack. N Engl J Med. 2006 Aug 10;355(6):54959.
4. American Heart Association. Heart disease and stroke statistics—2005 update. Dallas, Texas: American Heart Association 2005.
5. Available at: www.escardio.org/bodies/associations/EACPR/slides/EuroPrevent0. Accessed March 14, 2007.
6. Kent DM. Stroke—an equal opportunity for the initiation of statin therapy. N Engl J Med. 2006 Aug 10;355(6):613-5.
7. Anfossi G, Massucco P, Bonomo K, Trovati M. Prescription of statins to dyslipidemic patients affected by liver diseases: a subtle balance between risks and benefits. Nutr Metab Cardiovasc Dis. 2004 Aug;14(4):215-24.
8. Law M, Rudnicka AR. Statin safety: a systematic review. Am J Cardiol. 2006 Apr 17;97(8A):52C-60C.
9. Davis W. Cholesterol and Statin Drugs: separating hype from reality. Life Extension. 2005 Mar;11(3):114-24.
10. Cohen JS. Risks of troglitazone apparent before approval in USA. Diabetologia. 2006 Jun;49(6):1454-5.
11. Physicians' Desk Reference, 52nd and 54th Editions. Montvale, N.J.: Medical Economics Company, 1998 and 2000.
12. Cohen JS. Statin therapy after stroke or transient ischemic attack. N Engl J Med. 2006 Nov 30;355(22):2368.
13. Available at: www.bloomberg.com/apps/news?pid=20601086&sid=aU0FKY3RaHIM&refer=news. Accessed August 26, 2006.
14. Available at: www.boston.com. Accessed March 8, 2007.
15. Tuomilehto J, Guimaraes AC, Kettner H, et al. Doseresponse of simvastatin in primary hypercholesterolemia. J Cardiovasc Pharmacol. 1994 Dec;24(6):9419.
16. Williams RD. Medications and older adults. FDA Consumer magazine. Sept.-Oct. 1997.
17. Caso G, Kelly P, McNurlan MA, Lawson WE. Effect of coenzyme Q10 on myopathic symptoms in patients treated with statins. Am J Cardiol. 2007 May15;99(101):1409-12.
18. Studer M, Briel M, Leimenstoll B, Glass TR, Bucher HC. Effect of different antilipidemic agents and diet on mortality, a systematic review. Arch Intern Med. 2005 Apr;165(7):725-30.
19. Available at: www.medicinenet.com/script/main/art.asp?articlekey=18196.Accessed May 30, 2007.
20. Farswan M, Rathod SP, Upaganlawar AB, Semwal A. Protective effect of coenzyme Q10 in simvastatin and gemfibrozil induced rhabdomyolysis in rats. Indian J Exp Biol. 2005 Oct;43(10):845-8.
21. Lamperti C, Naini AB, Lucchini V, et al. Muscle coenzyme Q10 level in statin-related myopathy. Arch Neurol. 2005 Nov;62(11):1709-12.
22. Paiva H, Thelen KM, Van CR, et al. High-dose statins and skeletal muscle metabolism in humans: a randomized, controlled trial. Clin Pharmacol Ther. 2005 Jul;78(1):60-8.
23. Mabuchi H, Higashikata T, Kawashiri M, et al. Reduction of serum ubiquinol-10 and ubiquinone-10 levels by atorvastatin in hypercholesterolemic patients. J Atheroscler Thromb. 2005;12(2):111-9.
24. Thomas JE, Lee N, Thompson PD. Statins Provoking MELAS Syndrome. A Case Report. Eur Neurol. 2007 Mar 26;57(4):232-5.
25. Langsjoen PH, Langsjoen AM. The clinical use of HMG CoA-reductase inhibitors and the associated depletion of coenzyme Q10. A review of animal and human publications. Biofactors. 2003;18(1-4):101-11.
26. Langsjoen PH, Langsjoen JO, Langsjoen AM, Lucas LA. Treatment of statin adverse effects with supplemental Coenzyme Q10 and statin drug discontinuation. Biofactors. 2005;25(1-4):147-52.